Maximus vs Zealthy
Recorded prices, access and terms.
Decision table
The entries below are recorded provider statements unless a regulatory source is linked. A provider webpage does not independently verify its licenses or quality. Maximus source · Zealthy source.
| Compare | Maximus | Zealthy |
|---|---|---|
| Recorded medication/program subtotal | Monthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed. | Monthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed. |
| Full required monthly cost | Unconfirmed: consultation, labs, membership, dose changes and shipping must be checked | Unconfirmed: consultation, labs, membership, dose changes and shipping must be checked |
| Drug type listed | Compounded | Brand-name and compounded |
| Consultation | $28-35 per visit in the record; current conditions unconfirmed | $135/mo membership in the record; current conditions unconfirmed |
| Pharmacy license | Not independently verified. Obtain the dispensing pharmacy name and verify its state license. | Not independently verified. Obtain the dispensing pharmacy name and verify its state license. |
| Reported states | 50; confirm eligibility and clinician licensing in your state | 50; confirm eligibility and clinician licensing in your state |
| Cancellation | Cancellation reported; notice, minimum term and refund conditions unconfirmed | Cancellation reported; notice, minimum term and refund conditions unconfirmed |
| Clinician/support as reported | Licensed physicians, lab testing available | Licensed physicians, ongoing clinical support |
| Recorded provider check | No date recorded | No date recorded |
Which should you choose?
Ask each provider for the full cost at your prescribed dose, required labs and visits, the dispensing pharmacy, the clinician's state license, renewal charges and written refund terms. Compare those answers with your clinician.
Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or quality before marketing. FDA source and recommendations.
Maximus: evidence and terms
Recorded FDA letter (2026-06-08): Cited by FDA for false or misleading claims / misbranding in its telehealth marketing of compounded GLP-1 products. One of fifteen telehealth firms warned the same day. FDA letter.
Zealthy: evidence and terms
Recorded FDA letter (2025-09-09): FDA found claims on getzealthy.com for compounded GLP-1 products false or misleading, making the products misbranded under FD&C Act sections 502(a) and 502(bb). FDA letter.
Compare the full provider directory · Compare recorded price subtotals